Results 61 to 70 of about 70,211 (203)
PLoS ONE, 2019 BACKGROUND:Adjuvant endocrine treatment improves survival after estrogen receptor (ER) positive breast cancer. Recurrences occur, and most patients with metastatic breast cancer develop treatment resistance and incurable disease. An influential factor in
Annika Jögi +3 more
doaj +1 more source
Inducible arginase 1 deficiency in mice leads to hyperargininemia and altered amino acid metabolism [PDF]
, 2013 Arginase deficiency is a rare autosomal recessive disorder resulting from a loss of the liver arginase isoform, arginase 1 (ARG1), which is the final step in the urea cycle for detoxifying ammonia. ARG1 deficiency leads to hyperargininemia, characterized
Ballantyne, Laurel L. +6 more
core +7 more sources
Targeting interleukin-1β protects from aortic aneurysms induced by disrupted transforming growth factor β signaling [PDF]
, 2017 Aortic aneurysms are life-threatening conditions with effective treatments mainly limited to emergency surgery or trans-arterial endovascular stent grafts, thus calling for the identification of specific molecular targets.
Bizzotto, Dario +13 more
core +1 more source
Characterising the tumour morphological response to therapeutic intervention:an ex vivo model [PDF]
, 2012 In cancer, morphological assessment of histological tissue samples is a fundamental part of both diagnosis and prognosis. Image analysis offers opportunities to support that assessment through quantitative metrics of morphology.
Bown, James L. +6 more
core +5 more sources
Cells, 2019 Tamoxifen resistance is a major hurdle in the treatment of estrogen receptor (ER)-positive breast cancer. The mechanisms of tamoxifen resistance are not fully understood although several underlying molecular events have been suggested.
Angela Maselli +17 more
doaj +1 more source
EVALUATING THE THERAPEUTIC EFFICACY OF RESTORING WILD-TYPE P53 ACTIVITY IN P53-MUTANT TUMORS [PDF]
, 2017 The p53 transcription factor is the most frequently altered in human cancers usually via missense mutations that undermine its transcriptional activity. Clinically, TP53 mutations have been shown to be remarkably predictive of refractoriness to treatment,
Larsson, Connie A
core +1 more source
PRAS40 suppresses atherogenesis through inhibition of mTORC1-dependent pro-inflammatory signaling in endothelial cells [PDF]
, 2019 Endothelial pro-inflammatory activation plays a pivotal role in atherosclerosis, and many pro-inflammatory and atherogenic signals converge upon mechanistic target of rapamycin (mTOR).
Althoff, Till F. +14 more
core +1 more source
The Role of GLI-1 in Endocrine Resistant Breast Cancer [PDF]
, 2014 Estrogen receptor positive (ER+) and estrogen receptor negative (ER-) are two major types of breast cancer. For women with ER+ positive breast cancer, patients are treated with the antiestrogenic compounds, tamoxifen or faslodex for five years ...
Rudolph, Mark
core
Current medical treatment of estrogen receptor-positive breast cancer [PDF]
, 2015 Approximately 80% of breast cancers (BC) are estrogen receptor (ER)-positive and thus endocrine therapy (ET) should be considered complementary to surgery in the majority of patients.
Basso, S. M. M. +2 more
core +1 more source
Journal of Experimental & Clinical Cancer Research, 2019 Background Tamoxifen resistance presents a huge clinical challenge for breast cancer patients. An understanding of the mechanisms of tamoxifen resistance can guide development of efficient therapies to prevent drug resistance.
Fujun Li +8 more
doaj +1 more source